Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 172

1.

Glutamate and schizophrenia: beyond the dopamine hypothesis.

Coyle JT.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84. Epub 2006 Jun 14. Review.

PMID:
16773445
[PubMed - indexed for MEDLINE]
2.

Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.

Coyle JT, Tsai G, Goff D.

Ann N Y Acad Sci. 2003 Nov;1003:318-27. Review.

PMID:
14684455
[PubMed - indexed for MEDLINE]
3.

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.

Goff DC, Coyle JT.

Am J Psychiatry. 2001 Sep;158(9):1367-77. Review.

PMID:
11532718
[PubMed - indexed for MEDLINE]
4.

Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.

Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG.

Curr Top Med Chem. 2006;6(8):771-85. Review.

PMID:
16719816
[PubMed - indexed for MEDLINE]
5.

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.

Coyle JT, Tsai G.

Psychopharmacology (Berl). 2004 Jun;174(1):32-8. Epub 2003 Nov 25. Review.

PMID:
15205876
[PubMed - indexed for MEDLINE]
6.

[Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].

Hashimoto K, Iyo M.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2002 Feb;22(1):3-13. Review. Japanese.

PMID:
11917507
[PubMed - indexed for MEDLINE]
7.

[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].

Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.

Encephale. 2001 Jan-Feb;27(1):53-9. Review. French.

PMID:
11294039
[PubMed - indexed for MEDLINE]
8.

Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.

Pietraszek M.

Pol J Pharmacol. 2003 Mar-Apr;55(2):133-54. Review.

PMID:
12926541
[PubMed - indexed for MEDLINE]
Free Article
9.

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.

Shim SS, Hammonds MD, Kee BS.

Eur Arch Psychiatry Clin Neurosci. 2008 Feb;258(1):16-27. Epub 2007 Sep 27. Review.

PMID:
17901997
[PubMed - indexed for MEDLINE]
10.

The GABA-glutamate connection in schizophrenia: which is the proximate cause?

Coyle JT.

Biochem Pharmacol. 2004 Oct 15;68(8):1507-14. Review.

PMID:
15451393
[PubMed - indexed for MEDLINE]
11.

Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.

Javitt DC.

Int Rev Neurobiol. 2007;78:69-108. Review.

PMID:
17349858
[PubMed - indexed for MEDLINE]
12.

Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.

Coyle JT.

Neurotox Res. 2006 Dec;10(3-4):221-33. Review.

PMID:
17197372
[PubMed - indexed for MEDLINE]
13.

Glutamatergic mechanisms in schizophrenia.

Tsai G, Coyle JT.

Annu Rev Pharmacol Toxicol. 2002;42:165-79. Review.

PMID:
11807169
[PubMed - indexed for MEDLINE]
14.

Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.

Tsai GE, Lin PY.

Curr Pharm Des. 2010;16(5):522-37. Review.

PMID:
19909229
[PubMed - indexed for MEDLINE]
15.

Direct and indirect modulation of the N-methyl D-aspartate receptor.

Marino MJ, Conn PJ.

Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):1-16. Review.

PMID:
12769631
[PubMed - indexed for MEDLINE]
16.

Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.

Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G.

Handb Exp Pharmacol. 2012;(213):267-95. doi: 10.1007/978-3-642-25758-2_10. Review.

PMID:
23027419
[PubMed - indexed for MEDLINE]
17.

Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.

Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A.

Clin Ther. 2005;27 Suppl A:S16-24. Review.

PMID:
16198197
[PubMed - indexed for MEDLINE]
18.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.

Mol Pharmacol. 2010 Mar;77(3):317-26. doi: 10.1124/mol.109.059865. Epub 2009 Nov 23. Review. Erratum in: Mol Pharmacol. 2010 May;77(5):884.

PMID:
19933774
[PubMed - indexed for MEDLINE]
Free Article
19.

Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?

Large CH.

J Psychopharmacol. 2007 May;21(3):283-301. Review.

PMID:
17591656
[PubMed - indexed for MEDLINE]
20.

Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.

Laruelle M, Kegeles LS, Abi-Dargham A.

Ann N Y Acad Sci. 2003 Nov;1003:138-58. Review.

PMID:
14684442
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk